जर्नल ऑफ़ स्पीच पैथोलॉजी एंड थेरेपी

अमूर्त

M. R. Ponizovskiy, PhD, retired from the position of Head of the Toxicological and Biochemical Laboratory of the Kiev Regional P/N Hospital

Roni Moya

Immunotherapy, including the complementary immunotherapy for cancer, can be categorized as either specific or
nonspecific, both with the aim to enhance the immunity against tumors. A proper immunotherapy approach must
address a patient’s individual features of complexity such as tumor’s immune suppressive and pro-inflammatory
aspects, antigen heterogeneity and immunogenicity. The Active Autologous Specific Immunotherapy (ASI)
is capable of rearming and boosting the immune system against cancer by exclusively regulating patient’s own
immune-modulatory molecules.